For most sore throats caused by non-Group A streptococci, the honest answer is that nobody has proven treatment helps. Data on whether antibiotics relieve symptoms faster or prevent complications in Group C or Group G strep pharyngitis remain limited and conflicting, and major guidelines do not currently recommend routine antibiotic treatment for these infections the way they do for Group A strep. But the picture changes depending on which non-Group A species is involved, where in the body the infection is, and who the patient is.
Why the Question Is Harder Than It Sounds
When most people hear “strep throat,” they think of Group A Streptococcus (GAS), the bug that rapid strep tests are designed to catch. GAS is the reason antibiotics are prescribed for sore throats in the first place: treating it shortens illness, prevents spread, and reduces the risk of rheumatic fever and kidney complications. The clinical framework around strep throat was built almost entirely around this one species.
The trouble is that several other streptococcal groups can cause infections that look identical to GAS pharyngitis. Group C and Group G streptococci share similar biology with Group A and produce the same kind of exudative, painful sore throat that sends people to the doctor. Clinically, these infections are indistinguishable from one another.
1PubMed Central. Severe Acute Pharyngitis Caused by Group C Streptococcus Standard rapid antigen tests, however, are designed to detect only Group A strep. One study of rapid strep testing found that these tests systematically miss most cases of Group C and G streptococcal pharyngitis.2JAMA Internal Medicine. Management of Acute Pharyngitis in Adults: Reliability of Rapid Streptococcal Tests and Clinical Findings So a patient with a painful, pus-covered throat and a negative rapid strep test may actually have a non-GAS strep infection that the test simply was not built to find.
Beyond sore throats, the non-Group A strep family includes Group B streptococcus (well known in pregnancy but increasingly recognized as a serious pathogen in older adults), the Streptococcus anginosus group (notorious for forming abscesses), and the viridans group streptococci (usually harmless mouth bacteria that can turn dangerous in people with weakened immune systems). Each of these presents a different treatment calculus.
Group C and G Strep Pharyngitis
Group C and G strep together account for a meaningful minority of bacterial sore throats. In one pediatric study, Group A strep was isolated from about 22% of children with pharyngitis, while large-colony Group C and G strep appeared in roughly 3% of patients, about twice the rate seen in healthy controls, though that difference did not reach statistical significance.3Clinical Microbiology and Infection. The role of group C and group G streptococci in acute pharyngitis in children In adults, the species most commonly responsible, Streptococcus dysgalactiae subspecies equisimilis, shares enough genetic and biochemical machinery with Group A strep to produce nearly the same throat and skin infections.4PubMed Central. Infections Caused by Group C and G Streptococcus (Streptococcus dysgalactiae subsp. equisimilis and Others): Epidemiological and Clinical Aspects
Despite these similarities, no randomized trial has convincingly shown that antibiotic treatment of Group C or G strep pharyngitis shortens illness or prevents downstream complications. One widely cited review of the evidence concluded that the benefits of treating non-GAS pharyngitis “in terms of either symptomatic relief or prevention of sequelae are unproven.”5The Journal of the American Board of Family Medicine. Role of Non-Group A Streptococci in Acute Pharyngitis The same review noted that because the prevalence of these infections is relatively low and they are not convincingly linked to the serious complications seen with GAS, the clinical impact of missing them on a rapid test is probably small.2JAMA Internal Medicine. Management of Acute Pharyngitis in Adults: Reliability of Rapid Streptococcal Tests and Clinical Findings
This is the part that frustrates both patients and clinicians. You have a visibly infected throat, you feel terrible, the bacteria share many features with a known pathogen, and the official stance is essentially “we don’t have enough evidence to recommend antibiotics.” From a pure evidence standpoint, that position is defensible. From the exam room, it can feel unsatisfying.
Who Might Still Benefit from Treatment
Even researchers who caution against routine treatment of non-GAS pharyngitis carve out exceptions. The same review that called the benefits “unproven” suggested clinicians consider antibiotics for patients who fail to improve with symptomatic therapy alone, or who belong to higher-risk groups: people who are pregnant, newborns, the elderly, immunocompromised individuals, or people in close contact with any of these groups.5The Journal of the American Board of Family Medicine. Role of Non-Group A Streptococci in Acute Pharyngitis The reasoning is practical: if the downside of untreated infection could be severe in a vulnerable person, the relatively low risk of a short antibiotic course tips the balance toward treatment.
This is especially relevant for Group B strep, which is best known as a threat to newborns during birth but causes significant disease in adults too. Older adults account for more than 40% of invasive Group B strep cases and over half of the deaths associated with it in the United States.6PubMed. Group B streptococcal infections in elderly adults A population-based study found that the most common presentations in nonpregnant adults were skin and soft-tissue infections, bloodstream infections with no clear source, urinary tract infections, and pneumonia, with an overall mortality rate of 21%.7PubMed. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults Nobody debates whether to treat invasive Group B strep; the question of treatment only becomes ambiguous for milder, localized infections in otherwise healthy people.
The Complication Question
One of the main reasons Group A strep pharyngitis gets treated aggressively is to prevent rheumatic fever, an inflammatory condition that can damage the heart. For decades, the standard teaching was that non-GAS strep did not cause rheumatic fever, which was a key justification for not treating it. The evidence on this point is now less certain than textbooks once suggested.
A study of Aboriginal communities in Australia’s Northern Territory, where some of the highest rates of rheumatic fever in the world have been documented, found something puzzling: Group A strep throat carriage and symptomatic GAS pharyngitis were uncommon in this population, while Group C and G strep carriage rates were high. Researchers showed that these non-GAS streptococci had the potential to trigger the same kind of autoimmune response associated with rheumatic fever.8The Lancet. Group C and G streptococci and acute rheumatic fever A separate case report described a child who developed rheumatic heart disease attributed to Group C streptococcus.9PubMed. Group C Streptococcus Causing Rheumatic Heart Disease in a Child
These are not slam-dunk conclusions. The Australian findings raised the possibility of a link but did not prove direct causation, and single case reports carry obvious limitations. Acute post-streptococcal glomerulonephritis, a kidney complication of strep infection, is classically attributed to Group A strep,10PubMed Central. Acute post-streptococcal glomerulonephritis – immune-mediated acute kidney injury – case report and literature review and evidence linking it to other strep groups remains thin. Still, the assumption that non-GAS pharyngitis carries zero complication risk is looking less secure than it once did, particularly for Group C strep in certain populations.
When the Infection Goes Beyond the Throat
The treatment debate around non-GAS strep is really about two different clinical scenarios that sometimes get conflated. The first is mild pharyngitis in an otherwise healthy person, where the case for antibiotics is weak. The second is invasive or deep-seated infection, where antibiotics are unambiguously necessary and sometimes lifesaving.
Group G streptococcus, for instance, can cause streptococcal toxic shock syndrome, a rare but rapidly fatal condition involving organ failure and dangerously low blood pressure. A UK case series described successful management of three patients with toxic shock syndrome caused by Group G strep, reinforcing that this species can behave as aggressively as Group A in the right circumstances.11PubMed Central. Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom Group C and G strep can also cause peritonsillar abscesses, which can progress to deep neck infections including retropharyngeal abscesses and necrotizing fasciitis.12PubMed Central. Complications of peritonsillar abscess
The Streptococcus anginosus group occupies its own niche in the non-GAS world. These bacteria are part of the normal mouth and gut flora but have an unusual tendency to form abscesses in deep tissues, including the lungs, liver, and brain. Infections can range from wound infections and cellulitis to necrotizing fasciitis, lung abscesses, and pleural fistulas.13Scientific Reports. Clinical Characteristics of Infections Caused by Streptococcus Anginosus Group When an anginosus group species turns up in a culture from a deep abscess, treatment with antibiotics and often surgical drainage is standard practice. There is no controversy here: the bacteria have clearly invaded, and they need to be treated.
Similarly, viridans group streptococci, the large family of species that normally live quietly in your mouth, are generally harmless in healthy people but can cause endocarditis (heart valve infection), serious bloodstream infections, and septic shock in immunocompromised patients.14PubMed Central. It’s not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations Treatment is mandatory in these settings.
Group B Strep in Older Adults
Group B strep (GBS) deserves special attention because public awareness of it is almost entirely tied to pregnancy and newborns, leaving a significant blind spot. Invasive GBS disease in nonpregnant adults is rising, and it disproportionately affects older people and those with chronic illnesses. A systematic review found that the incidence of invasive GBS disease climbed steeply with age, reaching roughly 19 per 100,000 in adults aged 65 and older. Diabetes was the single most common underlying condition, present in 15 to 64% of cases. Cancer, cardiovascular disease, liver cirrhosis, kidney disease, and obesity also appeared frequently as comorbidities.15PLOS ONE. Burden of invasive group B streptococcus disease in non-pregnant adults: A systematic review and meta-analysis
About a quarter of healthy older adults carry GBS on their skin or in their gut without any symptoms, a colonization rate similar to that of women of childbearing age.6PubMed. Group B streptococcal infections in elderly adults The transition from harmless carriage to invasive disease likely depends on breaks in the skin, immune suppression, or surgical procedures creating an entry point. When GBS does invade, the consequences are serious: the 21% mortality rate in nonpregnant adults found in the population-based study mentioned earlier is far higher than most people would associate with a “strep infection.”7PubMed. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults Invasive GBS in adults always warrants antibiotic treatment, typically with penicillin or ampicillin.
The Delayed Prescribing Strategy
For the gray-zone cases, particularly sore throats where a non-GAS strep species is suspected but the infection is mild, a practical middle ground exists: delayed prescribing. The idea is that the clinician writes an antibiotic prescription but asks the patient to wait a few days before filling it, using it only if symptoms worsen or fail to improve.
A large individual patient data meta-analysis of delayed prescribing for respiratory tract infections found that the approach was essentially as effective as no antibiotics for all clinical outcomes, while offering higher patient satisfaction and fewer return visits for worsening symptoms.16PubMed Central. Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis In a randomized trial comparing several delayed prescribing strategies to immediate or no prescribing, there was no significant difference in symptom severity or duration between the groups, and antibiotic use was lowest in the no-prescription arm at 26% compared with an average of 37% in the delayed groups.17BMJ. Delayed antibiotic prescribing strategies for respiratory tract infections in primary care: pragmatic, factorial, randomised controlled trial
For non-GAS pharyngitis specifically, delayed prescribing respects the uncertainty in the evidence: you are not ignoring the infection, but you are not adding unnecessary antibiotic use to a situation where the benefits of immediate treatment are unproven. If the patient gets worse, the prescription is already in hand.
Antibiotic Resistance Patterns
One reason clinicians think carefully before prescribing antibiotics for infections of uncertain benefit is resistance. Group C and G streptococci remain generally susceptible to penicillin, which keeps first-line treatment straightforward when treatment is chosen. Resistance to macrolide antibiotics like erythromycin is a different story and follows different genetic pathways in the two groups. A Finnish study of erythromycin-resistant isolates found that 95% of resistant Group C strep carried a drug efflux gene, while 94% of resistant Group G strep carried a different resistance mechanism involving a methylase gene.18PubMed Central. Different erythromycin resistance mechanisms in group C and group G streptococci
This has practical implications for patients with penicillin allergies. Macrolides are a common alternative for penicillin-allergic patients with strep throat, but if your non-GAS infection happens to be caused by a macrolide-resistant strain, erythromycin or azithromycin might not work. In practice, local resistance patterns guide these decisions. The broader point is that treating non-GAS pharyngitis “just in case” carries a real cost in terms of driving resistance, which is part of why guidelines remain cautious.
Animal-to-Human Strep Transmission
An aspect of non-GAS strep that rarely comes up in routine clinical discussions is the zoonotic angle. Certain Group C streptococci, particularly Streptococcus equi subspecies zooepidemicus, are primarily animal pathogens that occasionally jump to humans with serious consequences. This species causes respiratory disease in horses and has been linked to human infections through direct contact with animals and through consumption of unpasteurized dairy or raw horse meat.
A case report documented what appears to be the first instance of S. equi subsp. zooepidemicus transmission from an infected dog to a handler, who then developed severe systemic infection. Molecular analysis confirmed the canine and human isolates were identical.19PubMed. Zoonotic transmission of Streptococcus equi subsp. zooepidemicus from a dog to a handler A separate review of human cases found infections in individuals with direct horse contact and in others who had consumed raw horse meat.20PubMed. Human zoonotic infectious disease caused by Streptococcus equi subsp. zooepidemicus Food-borne outbreaks involving non-GAS strep have also been documented in institutional settings: an outbreak of Group G strep pharyngitis at an Israeli military base in 1983 was traced to a food handler who was a convalescent carrier of the organism.21PubMed Central. Food-borne outbreak of group G streptococcal sore throat in an Israeli military base
Zoonotic strep infections are rare, but they tend to be more aggressive than typical community-acquired pharyngitis. When a non-GAS strep infection occurs in someone with animal exposure, particularly horses or dogs, clinicians should have a lower threshold for both culture-based identification and prompt antibiotic treatment. These are not “wait and see” scenarios.
What Rapid Tests Cannot Tell You
The diagnostic gap deserves emphasis because it shapes real-world decision-making more than any treatment guideline. Rapid antigen detection tests for strep throat are built to identify Group A strep only. They are fast and reasonably accurate for their intended target, but they are blind to every other streptococcal species. A negative rapid test does not mean there is no strep infection; it means there is no Group A strep infection.
Throat culture remains the gold standard for detecting non-GAS streptococci, but cultures take one to two days, and many clinics have shifted away from routine culturing in favor of the faster rapid tests. This means that Group C and G strep pharyngitis cases are likely underdiagnosed in everyday practice. If you have a sore throat that looks and feels like strep, your rapid test comes back negative, and you are not getting better after several days, it is reasonable to ask your clinician whether a throat culture or a repeat evaluation makes sense, especially if you fall into one of the higher-risk groups where treatment might be warranted.
The gap between what rapid tests can detect and what non-GAS strep can do is arguably the central tension in this whole debate. If you cannot easily identify the pathogen in routine practice, you cannot study it well in large populations, which means you cannot generate the randomized trial data that would settle the treatment question. The evidence vacuum is partly a diagnostic problem, not just a therapeutic one.